Table 2.

Western blot analysis: treatment effect within gender^a and gender^b differences(percentage density relative to total tau values)

	Insoluble tau: PHF1	Soluble tau: PHF1	Insoluble tau: MC1	Soluble tau: MC1
	M	F	M	F	M	F	M	F
2–5 months
Tg control	184 ± 35	96 ± 33	122 ± 15	169 ± 57	12 ± 3	17 ± 3	7 ± 1	3 ± 1+
Tg Phos-tau	116 ± 12	95 ± 13	282 ± 46**	218 ± 52	18 ± 6	27 ± 8	20 ± 9	7 ± 2*
2–8 months
Tg control	39 ± 11	96 ± 24	111 ± 15	55 ± 6++	11 ± 3	15 ± 6	54 ± 14	12 ± 4++
Tg Phos-tau	38 ± 13	68 ± 14	77 ± 14	62 ± 5	11 ± 2	32 ± 21	56 ± 13	9 ± 3++

^aTreatment effect within gender: In the 2−5 month study, significantly more effect of the immunization on pathological tau was observed between males in levels of soluble PHF1 tau and in females in levels of soluble MC1. *p ≤ 0.05, **p ≤ 0.01, significantly different from control mice within the same gender.

^bGender differences: Significant gender differences were observed between some of the groups, but these differences were not as prevalent as in the immunohistochemical analysis. In the 2−5 month study, male (n = 8) and female (n = 6) controls differed in soluble tau levels (MC1) but not Phos-tau-immunized males (n = 5) and females (n = 7). A similar pattern was observed in the immunohistochemical analysis with differences only observed in control groups. In the 2−8 month study (six males and six females per group), this difference was not as group specific with differences observed in soluble tau (MC1, PHF1) within controls. In the Phos-tau-immunized mice, gender differences were detected in soluble tau (MC1). ⁺p ≤ 0.05, ⁺⁺p ≤ 0.01, significantly different from males within the same treatment group.